Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Recombinant Granulocyte Colony-Stimulating Factor

Review the clinical trials studying recombinant granulocyte colony-stimulating factor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 54

Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Invasive Bladder Urothelial Cancer
Status: Active
Location: 369 locations
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Status: Active
Location: 167 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 206 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 144 locations
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Status: Active
Location: 16 locations
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Status: Active
Location: 14 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 8 locations
Brentuximab Vedotin in Early-Stage Hodgkin Lymphoma, RADAR Trial
Status: Active
Location: 5 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
Pembrolizumab after Neoadjuvant Chemotherapy followed by Surgery for the Treatment of Patients with Localized, Resectable Pancreatic Cancer
Status: Active
Location: 3 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Active
Location: 3 locations
Ex Vivo Expanded CD34+ Hematopoietic Stem Cells in Combination with Nivolumab for the Treatment of Recurrent, Progressive, or Refractory Pediatric High-grade Glioma
Status: Active
Location: 3 locations
Decitabine in Combination with Filgrastim Post-Hematopoietic Stem Cell Transplant in Preventing Relapse of Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Related Myeloid Malignancies in Pediatric and Young Adult Patients
Status: Active
Location: 2 locations
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Status: Active
Location: 2 locations
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Status: Active
Location: 2 locations
Specialized Stem Cell Transplant Product (CD34+ Selected Donor Cells) for the Treatment of Low Blood Counts after Donor Stem Cell Transplant
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Total Marrow and Lymphoid Irradiation as Conditioning Regimen before Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome or Acute Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Entrectinib for the Treatment of Patients Less Than 3 Years of Age with NTRK1/2/3 or ROS1 Fused High Grade Glioma or Other Central Nervous System Tumor
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee